Rheumatoid arthritis affects about 0.5% to 1% of adults worldwide, yet its impact can look bigger than the prevalence suggests when you factor in flares, disability, and work loss. In 2017 estimates, it contributed roughly 28 million years lived with disability, and cohorts show that around 1 in 3 people experience at least one flare each year. We will connect these burden figures to what drives outcomes and costs, from delayed treatment and cardiovascular mortality to serious infections and real world response to today’s targeted therapies.
Key Takeaways
- 0.5%–1% prevalence of rheumatoid arthritis among adults in many populations worldwide
- 1 in 3 people with rheumatoid arthritis are estimated to experience at least one flare every year (typical flare frequency reported in longitudinal studies)
- 3-year incidence rate: 0.3%–0.5% per year is commonly reported for rheumatoid arthritis in population-based studies
- Global burden: rheumatoid arthritis contributed roughly 28 million years lived with disability (YLDs) in 2017 estimates
- Rheumatoid arthritis accounts for major work impairment: 60% of patients report work disability at some point in longitudinal cohorts
- In the US, 16.7% of adults with arthritis (any type) report their arthritis limits their ability to work
- Rheumatoid arthritis is associated with increased risk of serious infections; 1.5–2.0% annual serious infection incidence is reported in cohorts on biologic therapy
- After 12 months of biologic therapy, ACR20 response rates are often around 50% in randomized trials (drug-specific; reported across classes)
- Methotrexate is the first-line conventional synthetic DMARD; clinical response rates to methotrexate are commonly reported with ACR20 around 50–60% in trials
- Global biologics and targeted synthetic DMARDs market growth: the rheumatoid arthritis biologics segment expanded materially in recent years (industry tracking by various analytics firms)
- US biologics spending: growth in pharmacy claims for RA biologics contributed to multi-billion-dollar annual expenditures (reported in national claims analyses)
- Global RA therapeutics: the market is tracked in the tens of billions of US dollars in multiple industry reports (published estimates vary by methodology)
- ADA adoption in payer policy: treat-to-target recommendations are incorporated into multiple guidelines; adoption by rheumatology practices is reflected in registry targets (major registries report increasing T2T adherence)
- Screening for tuberculosis prior to biologic or targeted therapy is standard; TB screening reduces active TB risk in biologic-treated cohorts (incident rates reported)
- Cardiovascular risk management is increasingly emphasized: RA guidelines recommend assessing CV risk at baseline and periodically (risk management standards reported in guidelines)
Rheumatoid arthritis affects about 0.5% to 1% of adults worldwide and can flare yearly.
Related reading
01 · Category
Epidemiology10 stats
01
0.5%–1% prevalence of rheumatoid arthritis among adults in many populations worldwide
02
1 in 3 people with rheumatoid arthritis are estimated to experience at least one flare every year (typical flare frequency reported in longitudinal studies)
03
3-year incidence rate: 0.3%–0.5% per year is commonly reported for rheumatoid arthritis in population-based studies
04
The median age of onset for rheumatoid arthritis is around 60 years
05
10.0% of adults in the US report diagnosis of arthritis (any type) in surveys (RA included among types)
06
Rheumatoid arthritis is classified as an autoimmune disease and is among the most common inflammatory arthritides with systematic epidemiology reviews
07
Up to 10% of people with inflammatory arthritis may have rheumatoid arthritis in some epidemiology cohorts (proportions reported in systematic reviews)
08
Smoking association: current smoking increases risk of developing seropositive rheumatoid arthritis; relative risk estimates are quantified in meta-analyses
09
Periodontal disease association: severe periodontitis is associated with increased RA risk; effect sizes are reported in observational studies
10
Anti-citrullinated peptide antibodies (ACPA) positivity is observed in roughly 60–75% of RA patients in clinical cohorts
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, rheumatoid arthritis affects about 0.5% to 1% of adults worldwide, with a typical incidence of 0.3% to 0.5% per year, and although many cases are diagnosed around age 60, roughly 1 in 3 people experience at least one flare each year.
02 · Category
Burden & Disability8 stats
01
Global burden: rheumatoid arthritis contributed roughly 28 million years lived with disability (YLDs) in 2017 estimates
02
Rheumatoid arthritis accounts for major work impairment: 60% of patients report work disability at some point in longitudinal cohorts
03
In the US, 16.7% of adults with arthritis (any type) report their arthritis limits their ability to work
04
In people with rheumatoid arthritis, cardiovascular disease is a leading cause of excess mortality (relative risk reported in meta-analyses)
05
Work productivity loss: RA is linked to reduced work participation; studies quantify percentage not working or limited work among RA patients
06
Mortality gap: excess deaths in RA relative to general population are quantified in population studies and meta-analyses (relative risk measures reported)
07
Disability: RA is associated with increased risk of progression to severe disability; longitudinal studies quantify disability progression rates
08
Productivity effects: RA is associated with increased absenteeism; cohort studies quantify average missed work days
Interpretation
Burden & Disability Interpretation
Rheumatoid arthritis places a heavy burden on daily life and work, contributing about 28 million years lived with disability in 2017 and affecting productivity as 60% of patients report work disability at some point, with additional evidence that RA is linked to increased absenteeism and higher excess mortality.
03 · Category
Treatment & Outcomes15 stats
01
Rheumatoid arthritis is associated with increased risk of serious infections; 1.5–2.0% annual serious infection incidence is reported in cohorts on biologic therapy
02
After 12 months of biologic therapy, ACR20 response rates are often around 50% in randomized trials (drug-specific; reported across classes)
03
Methotrexate is the first-line conventional synthetic DMARD; clinical response rates to methotrexate are commonly reported with ACR20 around 50–60% in trials
04
Treat-to-target strategies can achieve low disease activity or remission in about 50% of patients by 1 year in clinical studies
05
Time to diagnosis and treatment is critical: delays of >6 months to initiating DMARDs are associated with worse outcomes in observational cohorts
06
Radiographic progression can be slowed: treat-to-target with early DMARDs reduces erosions compared with conventional management (reported in trials)
07
JAK inhibitor class: in randomized trials, ACR20 response at ~3 months is often around 70% for dose-dependent regimens (example: tofacitinib)
08
Methotrexate remains the most prescribed DMARD globally as first-line for RA (distribution reported in treatment surveys and registries)
09
Glucocorticoid use: observational studies report that a substantial fraction of RA patients receive oral glucocorticoids at some point during treatment courses (percentage in cohorts)
10
Biologic DMARD monotherapy is used in a subset of patients; registry analyses report percentages depending on contraindications (quantified in studies)
11
EULAR recommendations: stable remission can justify DMARD tapering in selected patients; guideline reports criteria and proportions in trials
12
JAK inhibitor safety: in large trials, serious infection rates were reported as events per 100 patient-years and are similar across comparators in many analyses (rates quantified)
13
Ulcerative colitis and RA share inflammation targets; RA targeted therapies are measured by cytokine pathway inhibition (quantified response in trials)
14
Patient-reported outcomes: HAQ-DI is commonly used; clinically meaningful improvement is typically defined as a change of about 0.22 units in RA
15
Minimum clinically important difference: EULAR response uses standard cutoffs in composite measures, with defined thresholds for improvement
Interpretation
Treatment & Outcomes Interpretation
Across Treatment & Outcomes, the strongest trend is that modern treat-to-target RA care can drive meaningful improvement in about half of patients by 1 year, yet the tradeoff is ongoing safety risk with serious infections occurring at roughly 1.5 to 2.0% per year even on biologic therapy.
More related reading
04 · Category
Market Size3 stats
01
Global biologics and targeted synthetic DMARDs market growth: the rheumatoid arthritis biologics segment expanded materially in recent years (industry tracking by various analytics firms)
02
US biologics spending: growth in pharmacy claims for RA biologics contributed to multi-billion-dollar annual expenditures (reported in national claims analyses)
03
Global RA therapeutics: the market is tracked in the tens of billions of US dollars in multiple industry reports (published estimates vary by methodology)
Interpretation
Market Size Interpretation
The market size evidence shows rheumatoid arthritis is already a tens of billions of US dollars opportunity, with US RA biologics driving multi billion-dollar annual pharmacy claim spend and global biologics and targeted synthetic DMARD growth expanding materially in recent years.
05 · Category
Industry Trends8 stats
01
ADA adoption in payer policy: treat-to-target recommendations are incorporated into multiple guidelines; adoption by rheumatology practices is reflected in registry targets (major registries report increasing T2T adherence)
02
Screening for tuberculosis prior to biologic or targeted therapy is standard; TB screening reduces active TB risk in biologic-treated cohorts (incident rates reported)
03
Cardiovascular risk management is increasingly emphasized: RA guidelines recommend assessing CV risk at baseline and periodically (risk management standards reported in guidelines)
04
Vaccination uptake: annual influenza vaccination rates in RA patients are often around 50% or less in surveys (reported in observational studies)
05
Rheumatoid arthritis specialty care models: many systems use nurse-led follow-up; registry evaluations report reduced time to medication adjustment (measurable outcome in studies)
06
Rheumatoid arthritis drug pipeline: multiple novel mechanisms (e.g., IL-6, BTK, T-cell pathways) are in clinical development; counts of active trials are reported in clinical trial registries
07
In clinical trial registries, rheumatoid arthritis has thousands of registered studies globally across phases (counts vary by date and filters)
08
First-year retention on biologics: real-world registry studies report about 70% of patients remain on their initial biologic at 12 months (varies by agent)
Interpretation
Industry Trends Interpretation
Industry Trends in rheumatoid arthritis show that treat to target is becoming mainstream and biologic retention is strong, with real-world registries reporting about 70% of patients staying on their first biologic at 12 months while active TB and cardiovascular risk screening and nurse-led specialty models support this shift in care delivery.
06 · Category
Cost Analysis12 stats
01
Long-term drug switching: persistent switching due to lack of response contributes to cumulative cost; real-world persistence/switching studies quantify switching rates
02
In the UK, the availability of home-based biologic administration can reduce indirect costs; economic evaluations report differences in total cost (reported in published cost-effectiveness analyses)
03
US direct medical costs: rheumatoid arthritis has been estimated at roughly $20,000+ per patient per year (direct medical expenditures reported in economic studies)
04
Indirect costs: productivity loss is a major component in RA; studies estimate thousands of dollars per patient annually in work-related costs
05
Hospitalizations: serious infections requiring hospitalization are a key cost driver; incidence and hospitalization costs are quantified in claims studies (rates and cost amounts reported)
06
Dose and route: biologic dosing intervals (e.g., every 2–8 weeks depending on agent) lead to predictable administration cost components quantified in health economic models
07
Infusion vs injection administration: economic analyses report lower administration cost for self-injection programs versus infusion center administration (cost differences in studies)
08
Prior authorization: specialty drugs often require step therapy; payer administrative burden is quantified in policy-impact analyses (administrative time/cost reported)
09
High out-of-pocket burden: in surveys, a notable share of patients with RA report medication cost-related nonadherence (percent reporting observed in studies)
10
Medical costs rise with disease severity: economic studies show substantially higher annual costs for patients with moderate/severe disease activity versus remission
11
Comorbidities add cost: RA with cardiovascular comorbidities has higher annual healthcare expenditures in administrative claims studies
12
Costs in the US: total annual national economic burden of RA has been estimated in hundreds of billions when direct and indirect costs are aggregated (estimates reported in economic reviews)
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, rheumatoid arthritis can run more than $20,000 per patient per year in US direct medical spending and, when you add productivity losses, hospitalization-driven infection costs, and rising expenses with worsening disease severity, the overall national burden reaches hundreds of billions, showing that real-world costs are escalating well beyond drug prices alone.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Catherine Wu. (2026, February 13). Rheumatoid Arthritis Statistics. Gitnux. https://gitnux.org/rheumatoid-arthritis-statistics
MLA
Catherine Wu. "Rheumatoid Arthritis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/rheumatoid-arthritis-statistics.
Chicago
Catherine Wu. 2026. "Rheumatoid Arthritis Statistics." Gitnux. https://gitnux.org/rheumatoid-arthritis-statistics.
Sources & references
56 datasets cited across this report · attribution is report-level
nhs.uk
ard.bmj.com
academic.oup.com
nature.com
thelancet.com
sciencedirect.com
cdc.gov
ahajournals.org
nejm.org
ncbi.nlm.nih.gov
alliedmarketresearch.com
jamanetwork.com
fortunebusinessinsights.compubmed.ncbi.nlm.nih.gov
clinicaltrials.govbmj.com
+40 additional datasets cited (not shown individually)